A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.

Trial Details

NCT ID
NCT06629779
Phase
PHASE3
Sponsor
Pfizer
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • PF-06821497
  • Placebo
  • Enzalutamide
Locations (sample)
  • Chandler, Arizona, United States|33.30616,-111.84125
  • Goodyear, Arizona, United States|33.43532,-112.35821
  • Fayetteville, Arkansas, United States|36.06258,-94.15743
  • Rogers, Arkansas, United States|36.33202,-94.11854
  • Anaheim, California, United States|33.83529,-117.9145

Key Eligibility Criteria

  • Histologically or cytologically confirmed adenocarcinoma of the prostate without small cell features.
  • Metastatic disease in bone documented on bone scan, or in soft tissue documented on CT/MRI scan.
  • Progressive disease in the setting of medical or surgical castration.
  • ECOG performance status 0 or 1, with a life expectancy of ≥12 months as assessed by the investigator.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →